Cytokines in idiopathic inflammatory myopathies

References

• Elliott MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Katsikis P, Brennan FM, Walker J, Bijl H, Ghrayeb J, et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum 1993; 36: 1681–1690
   PubMed Web of Science ®Google Scholar
• van Dullemen HM, van Deventer SJ, Hommes DW, Bijl HA, Jansen J, Tytgat GN, Woody J. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 1995; 109: 129–135
   PubMed Web of Science ®Google Scholar
• Lundberg IE. Clinical symptoms in patients with myositis-an acquired metabolic myopathy?. Curr Opin Rheumatol 2003; 15: 675–678
   PubMed Web of Science ®Google Scholar
• Arahata K, Engel AG. Monoclonal antibody analysis of mononuclear cells in myopathies. I: Quantitation of subsets according to diagnosis and sites of accumulation and demonstration and counts of muscle fibers invaded by T cells. Ann Neurol 1984; 16: 193–208
   PubMed Web of Science ®Google Scholar
• Engel AG, Arahata K. Monoclonal antibody analysis of mononuclear cells in myopathies. II: Phenotypes of autoinvasive cells in polymyositis and inclusion body myositis. Ann Neurol 1984; 16: 209–215
   PubMed Web of Science ®Google Scholar
• Karpati G, Pouliot Y, Carpenter S. Expression of immunoreactive major histocompatibility complex products in human skeletal muscles. Ann Neurol 1988; 23: 64–72
   PubMed Web of Science ®Google Scholar
• Emslie-Smith AM, Arahata K, Engel AG. Major histocompatibility complex class I antigen expression, immunolocalization of interferon subtypes, and T cell-mediated cytotoxicity in myopathies. Hum Pathol 1989; 20: 224–231
   PubMed Web of Science ®Google Scholar
• Lundberg I, Brengman JM, Engel AG. Analysis of cytokine expression in muscle in inflammatory myopathies. Duchenne dystrophy, and non-weak controls. J Neuroimmunol 1995; 63: 9–16
   PubMed Web of Science ®Google Scholar
• Lindberg C, Oldfors A, Tarkowski A. Local T-cell proliferation and differentiation in inflammatory myopathies. Scand J Immunol 1995; 41: 421–426
   PubMedGoogle Scholar
• Tews DS, Goebel HH. Cytokine expression profile in idiopathic inflammatory myopathies. J Neuropathol Exp Neurol 1996; 55: 342–347
   PubMed Web of Science ®Google Scholar
• Nyberg P, Wikman AL, Nennesmo I, Lundberg I. Increased expression of interleukin 1alpha and MHC class I in muscle tissue of patients with chronic, inactive polymyositis and dermatomyositis. J Rheumatol 2000; 27: 940–948
   PubMedGoogle Scholar
• Englund P, Lindroos E, Nennesmo I, Klareskog L, Lundberg IE. Skeletal muscle fibers express major histocompatibility complex class II antigens independently of inflammatory infiltrates in inflammatory myopathies. Am J Pathol 2001; 159: 1263–1273
   PubMedGoogle Scholar
• Englund P, Nennesmo I, Klareskog L, Lundberg IE. Interleukin-1alpha expression in capillaries and major histocompatibility complex class I expression in type II muscle fibers from polymyositis and dermatomyositis patients: Important pathogenic features independent of inflammatory cell clusters in muscle tissue. Arthritis Rheum 2002; 46: 1044–1055
   PubMedGoogle Scholar
• Nagaraju K, Raben N, Merritt G, Loeffler L, Kirk K, Plotz P. A variety of cytokines and immunologically relevant surface molecules are expressed by normal human skeletal muscle cells under proinflammatory stimuli. Clin Exp Immunol 1998; 113: 407–414
   PubMed Web of Science ®Google Scholar
• Nagaraju K, Raben N, Loeffler L, Parker T, Rochon PJ, Lee E, Danning C, Wada R, Thompson C, Bahtiyar G, et al. Conditional up-regulation of MHC class I in skeletal muscle leads to self-sustaining autoimmune myositis and myositis-specific autoantibodies. Proc Natl Acad Sci USA 2000; 97: 9209–9214
   PubMed Web of Science ®Google Scholar
• Wolf RE, Baethge BA. Interleukin-1 alpha, interleukin-2, and soluble interleukin-2 receptors in polymyositis. Arthritis Rheum 1990; 33: 1007–1014
   PubMedGoogle Scholar
• Fang CH, Li BG, James JH, Fischer JE, Hasselgren PO. Cytokines block the effects of insulin-like growth factor-I (IGF-I) on glucose uptake and lactate production in skeletal muscle but do not influence IGF-I-induced changes in protein turnover. Shock 1997; 8: 362–367
   PubMedGoogle Scholar
• Lecker SH, Solomon V, Mitch WE, Goldberg AL. Muscle protein breakdown and the critical role of the ubiquitin-proteasome pathway in normal and disease states. J Nutr 1999; 129(1S Suppl)227S–237S
   Google Scholar
• Quinn LS, Haugk KL, Grabstein KH. Interleukin-15: A novel anabolic cytokine for skeletal muscle. Endocrinology 1995; 136: 3669–3672
   PubMed Web of Science ®Google Scholar
• DeVere R, Bradley WG. Polymyositis: Its presentation, morbidity and mortality. Brain 1975; 98: 637–666
   PubMed Web of Science ®Google Scholar
• Lundberg I, Ulfgren AK, Nyberg P, Andersson U, Klareskog L. Cytokine production in muscle tissue of patients with idiopathic inflammatory myopathies. Arthritis Rheum 1997; 40: 865–874
   PubMed Web of Science ®Google Scholar
• Lepidi H, Frances V, Figarella-Branger D, Bartoli C, Machado-Baeta A, Pellissier JF. Local expression of cytokines in idiopathic inflammatory myopathies. Neuropathol Appl Neurobiol 1998; 24: 73–79
   PubMed Web of Science ®Google Scholar
• Lundberg I, Kratz AK, Alexanderson H, Patarroyo M. Decreased expression of interleukin-1alpha, interleukin-1beta, and cell adhesion molecules in muscle tissue following corticosteroid treatment in patients with polymyositis and dermatomyositis. Arthritis Rheum 2000; 43: 336–348
   PubMed Web of Science ®Google Scholar
• Dinarello CA. Biologic basis for interleukin-1 in disease. Blood 1996; 87: 2095–2147
   PubMed Web of Science ®Google Scholar
• Mantovani A, Bussolino F, Dejana E. Cytokine regulation of endothelial cell function. FASEB J 1992; 6: 2591–2599
   PubMed Web of Science ®Google Scholar
• Wicks IP, Leizer T, Wawryk SO, Novotny JR, Hamilton J, Vitti G, Boyd AW. The effect of cytokines on the expression of MHC antigens and ICAM-1 by normal and transformed synoviocytes. Autoimmunity 1992; 12: 13–19
   PubMed Web of Science ®Google Scholar
• Ogawa S, Shreeniwas R, Brett J, Clauss M, Furie M, Stern DM. The effect of hypoxia on capillary endothelial cell function: Modulation of barrier and coagulant function. Br J Haematol 1990; 75: 517–524
   PubMed Web of Science ®Google Scholar
• Shreeniwas R, Koga S, Karakurum M, Pinsky D, Kaiser E, Brett J, Wolitzky BA, Norton C, Plocinski J, Benjamin W, et al. Hypoxia-mediated induction of endothelial cell interleukin-1 alpha. An autocrine mechanism promoting expression of leukocyte adhesion molecules on the vessel surface. J Clin Invest 1992; 90: 2333–2339
   PubMed Web of Science ®Google Scholar
• Authier FJ, Mhiri C, Chazaud B, Christov C, Cherin P, Barlovatz-Meimon G, Gherardi RK. Interleukin-1 expression in inflammatory myopathies: Evidence of marked immunoreactivity in sarcoid granulomas and muscle fibres showing ischaemic and regenerative changes. Neuropathol Appl Neurobiol 1997; 23: 132–140
   PubMedGoogle Scholar
• Ghezzi P, Dinarello CA, Bianchi M, Rosandich ME, Repine JE, White CW. Hypoxia increases production of interleukin-1 and tumor necrosis factor by human mononuclear cells. Cytokine 1991; 3: 189–194
   PubMed Web of Science ®Google Scholar
• Gabay C, Gay-Croisier F, Roux-Lombard P, Meyer O, Maineti C, Guerne PA, Vischer T, Dayer JM. Elevated serum levels of interleukin-1 receptor antagonist in polymyositis/dermatomyositis. A biologic marker of disease activity with a possible role in the lack of acute-phase protein response. Arthritis Rheum 1994; 37: 1744–1751
   PubMed Web of Science ®Google Scholar
• Arend WP. Interleukin-1 receptor antagonist. Adv Immunol 1993; 54: 167–227
   PubMed Web of Science ®Google Scholar
• Banda NK, Guthridge C, Sheppard D, Cairns KS, Muggli M, Bech-Otschir D, Dubiel W, Arend WP. Intracellular IL-1 receptor antagonist type 1 inhibits IL-1-induced cytokine production in keratinocytes through binding to the third component of the COP9 signalosome. J Immunol 2005; 174: 3608–3616
   PubMed Web of Science ®Google Scholar
• Ma Y, Thornton S, Boivin GP, Hirsh D, Hirsch R, Hirsch E. Altered susceptibility to collagen-induced arthritis in transgenic mice with aberrant expression of interleukin-1 receptor antagonist. Arthritis Rheum 1998; 41: 1798–1805
   PubMed Web of Science ®Google Scholar
• Prieur AM, Dayer A, Roux-Lombard P, Dayer JM. Levels of cytokine inhibitors: A possible marker of disease activity in childhood dermatomyositis and polymyositis. Clin Exp Rheumatol 1997; 15: 211–214
   PubMedGoogle Scholar
• Rider LG, Artlett CM, Foster CB, Ahmed A, Neeman T, Chanock SJ, Jimenez SA, Miller FW. Polymorphisms in the IL-1 receptor antagonist gene VNTR are possible risk factors for juvenile idiopathic inflammatory myopathies. Clin Exp Immunol 2000; 121: 47–52
   PubMedGoogle Scholar
• Greenfeder SA, Nunes P, Kwee L, Labow M, Chizzonite RA, Ju G. Molecular cloning and characterization of a second subunit of the interleukin 1 receptor complex. J Biol Chem 1995; 270: 13757–13765
   PubMed Web of Science ®Google Scholar
• Zhang Y, Pilon G, Marette A, Baracos VE. Cytokines and endotoxin induce cytokine receptors in skeletal muscle. Am J Physiol Endocrinol Metab 2000; 279: E196–E205
   PubMed Web of Science ®Google Scholar
• Grundtman C, Salomonsson S, Dorph C, Bruton J, Andersson U, Lundberg IE. Marked expression of IL-1 receptors in cell nuclei and muscle fiber membrane in muscle tissue of patients with idiopathic inflammatory myopathies. Arthritis Res Ther 2005; 7(Suppl 1)S33, Abstract P85, European Workshop for Rheumatology Research. Glasgow, UK, 24–27 February
   Google Scholar
• Ghayur T, Banerjee S, Hugunin M, Butler D, Herzog L, Carter A, Quintal L, Sekut L, Talanian R, Paskind M, et al. Caspase-1 processes IFN-gamma-inducing factor and regulates LPS-induced IFN-gamma production. Nature 1997; 386: 619–623
   PubMed Web of Science ®Google Scholar
• Stoll S, Muller G, Kurimoto M, Saloga J, Tanimoto T, Yamauchi H, Okamura H, Knop J, Enk AH. Production of IL-18 (IFN-gamma-inducing factor) messenger RNA and functional protein by murine keratinocytes. J Immunol 1997; 159: 298–302
   PubMed Web of Science ®Google Scholar
• Stoll S, Jonuleit H, Schmitt E, Muller G, Yamauchi H, Kurimoto M, Knop J, Enk AH. Production of functional IL-18 by different subtypes of murine and human dendritic cells (DC): DC-derived IL-18 enhances IL-12-dependent Th1 development. Eur J Immunol 1998; 28: 3231–3239
   PubMed Web of Science ®Google Scholar
• Okamura H, Tsutsi H, Komatsu T, Yutsudo M, Hakura A, Tanimoto T, Torigoe K, Okura T, Nukada Y, Hattori K, et al. Cloning of a new cytokine that induces IFN-gamma production by T cells. Nature 1995; 378: 88–91
   PubMed Web of Science ®Google Scholar
• Dinarello CA. Interleukin-18. Methods 1999; 19: 121–132
   PubMed Web of Science ®Google Scholar
• Morel JC, Park CC, Zhu K, Kumar P, Ruth JH, Koch AE. Signal transduction pathways involved in rheumatoid arthritis synovial fibroblast interleukin-18-induced vascular cell adhesion molecule-1 expression. J Biol Chem 2002; 277: 34679–34691
   PubMed Web of Science ®Google Scholar
• Dai SM, Matsuno H, Nakamura H, Nishioka K, Yudoh K. Interleukin-18 enhances monocyte tumor necrosis factor alpha and interleukin-1beta production induced by direct contact with T lymphocytes: Implications in rheumatoid arthritis. Arthritis Rheum 2004; 50: 432–443
   PubMed Web of Science ®Google Scholar
• Gracie JA, Forsey RJ, Chan WL, Gilmour A, Leung BP, Greer MR, Kennedy K, Carter R, Wei XQ, Xu D, et al. A proinflammatory role for IL-18 in rheumatoid arthritis. J Clin Invest 1999; 104: 1393–1401
   PubMed Web of Science ®Google Scholar
• Yamamura M, Kawashima M, Taniai M, Yamauchi H, Tanimoto T, Kurimoto M, Morita Y, Ohmoto Y, Makino H. Interferon-gamma-inducing activity of interleukin-18 in the joint with rheumatoid arthritis. Arthritis Rheum 2001; 44: 275–285
   PubMed Web of Science ®Google Scholar
• Joosten LA, Radstake TR, Lubberts E, van den Bersselaar LA, van Riel PL, van Lent PL, Barrera P, van den Berg WB. Association of interleukin-18 expression with enhanced levels of both interleukin-1beta and tumor necrosis factor alpha in knee synovial tissue of patients with rheumatoid arthritis. Arthritis Rheum 2003; 48: 339–347
   PubMed Web of Science ®Google Scholar
• Rooney T, Murphy E, Benito M, Roux-Lombard P, FitzGerald O, Dayer JM, Bresnihan B. Synovial tissue interleukin-18 expression and the response to treatment in patients with inflammatory arthritis. Ann Rheum Dis 2004; 63: 1393–1398
   PubMed Web of Science ®Google Scholar
• Lundberg IE, Barbasso S, Ulfgren A, Gracie JA, McInnes IB. Expression of IL-18 in muscle tissue of patients with treatment resistant idiopathic inflammatory myopathies. Arthritis Res Ther 2005; 7(Suppl 1)S23, Abstract P57, European Workshop for Rheumatology Research. Glasgow, UK, 24–27 February
   Google Scholar
• Gracie JA, Robertson SE, McInnes IB. Interleukin-18. J Leukoc Biol 2003; 73: 213–224
   PubMed Web of Science ®Google Scholar
• Novick D, Kim SH, Fantuzzi G, Reznikov LL, Dinarello CA, Rubinstein M. Interleukin-18 binding protein: A novel modulator of the Th1 cytokine response. Immunity 1999; 10: 127–136
   PubMed Web of Science ®Google Scholar
• Corbaz A, ten Hove T, Herren S, Graber P, Schwartsburd B, Belzer I, Harrison J, Plitz T, Kosco-Vilbois MH, Kim SH, et al. IL-18-binding protein expression by endothelial cells and macrophages is up-regulated during active Crohn's disease. J Immunol 2002; 168: 3608–3616
   PubMedGoogle Scholar
• Goetz FW, Planas JV, MacKenzie S. Tumor necrosis factors. Dev Comp Immunol 2004; 28: 487–497
   PubMed Web of Science ®Google Scholar
• Michaelis D, Goebels N, Hohlfeld R. Constitutive and cytokine-induced expression of human leukocyte antigens and cell adhesion molecules by human myotubes. Am J Pathol 1993; 143: 1142–1149
   PubMedGoogle Scholar
• Tateyama M, Nagano I, Yoshioka M, Chida K, Nakamura S, Itoyama Y. Expression of tumor necrosis factor-alpha in muscles of polymyositis. J Neurol Sci 1997; 146: 45–51
   PubMedGoogle Scholar
• De Bleecker JL, Meire VI, Declercq W, Van Aken EH. Immunolocalization of tumor necrosis factor-alpha and its receptors in inflammatory myopathies. Neuromuscul Disord 1999; 9: 239–246
   PubMed Web of Science ®Google Scholar
• Kuru S, Inukai A, Kato T, Liang Y, Kimura S, Sobue G. Expression of tumor necrosis factor-alpha in regenerating muscle fibers in inflammatory and non-inflammatory myopathies. Acta Neuropathol (Berl) 2003; 105: 217–224
   PubMed Web of Science ®Google Scholar
• Seko Y, Matsuda H, Kato K, Hashimoto Y, Yagita H, Okumura K, Yazaki Y. Expression of intercellular adhesion molecule-1 in murine hearts with acute myocarditis caused by coxsackievirus B3. J Clin Invest 1993; 91: 1327–1336
   PubMedGoogle Scholar
• Scheurich P, Thoma B, Ucer U, Pfizenmaier K. Immunoregulatory activity of recombinant human tumor necrosis factor (TNF)-alpha: Induction of TNF receptors on human T cells and TNF-alpha-mediated enhancement of T cell responses. J Immunol 1987; 138: 1786–1790
   PubMed Web of Science ®Google Scholar
• Tracey KJ, Lowry SF, Beutler B, Cerami A, Albert JD, Shires GT. Cachectin/tumor necrosis factor mediates changes of skeletal muscle plasma membrane potential. J Exp Med 1986; 164: 1368–1373
   PubMed Web of Science ®Google Scholar
• Miller SC, Ito H, Blau HM, Torti FM. Tumor necrosis factor inhibits human myogenesis in vitro. Mol Cell Biol 1988; 8: 2295–2301
   PubMed Web of Science ®Google Scholar
• Lee MD, Zentella A, Vine W, Pekala PH, Cerami A. Effect of endotoxin-induced monokines on glucose metabolism in the muscle cell line L6. Proc Natl Acad Sci USA 1987; 84: 2590–2594
   PubMed Web of Science ®Google Scholar
• Flores EA, Bistrian BR, Pomposelli JJ, Dinarello CA, Blackburn GL, Istfan NW. Infusion of tumor necrosis factor/cachectin promotes muscle catabolism in the rat. A synergistic effect with interleukin 1. J Clin Invest 1989; 83: 1614–1622
   PubMed Web of Science ®Google Scholar
• Goodman MN. Tumor necrosis factor induces skeletal muscle protein breakdown in rats. Am J Physiol 1991; 260(5 Pt 1)E727–E730
   Google Scholar
• Garcia-Martinez C, Agell N, Llovera M, Lopez-Soriano FJ, Argiles JM. Tumour necrosis factor-alpha increases the ubiquitinization of rat skeletal muscle proteins. FEBS Lett 1993; 323: 211–214
   PubMedGoogle Scholar
• Reid MB, Lannergren J, Westerblad H. Respiratory and limb muscle weakness induced by tumor necrosis factor-alpha: Involvement of muscle myofilaments. Am J Respir Crit Care Med 2002; 166: 479–484
   PubMed Web of Science ®Google Scholar
• Heller RA, Kronke M. Tumor necrosis factor receptor-mediated signaling pathways. J Cell Biol 1994; 126: 5–9
   PubMed Web of Science ®Google Scholar
• Slowik MR, De Luca LG, Fiers W, Pober JS. Tumor necrosis factor activates human endothelial cells through the p55 tumor necrosis factor receptor but the p75 receptor contributes to activation at low tumor necrosis factor concentration. Am J Pathol 1993; 143: 1724–1730
   PubMedGoogle Scholar
• Mackay F, Loetscher H, Stueber D, Gehr G, Lesslauer W. Tumor necrosis factor alpha (TNF-alpha)-induced cell adhesion to human endothelial cells is under dominant control of one TNF receptor type, TNF-R55. J Exp Med 1993; 177: 1277–1286
   PubMed Web of Science ®Google Scholar
• Barbara JA, Smith WB, Gamble JR, Van Ostade X, Vandenabeele P, Tavernier J, Fiers W, Vadas MA, Lopez AF. Dissociation of TNF-alpha cytotoxic and proinflammatory activities by p55 receptor- and p75 receptor-selective TNF-alpha mutants. EMBO J 1994; 13: 843–850
   PubMed Web of Science ®Google Scholar
• Tartaglia LA, Pennica D, Goeddel DV. Ligand passing: The 75 kDa tumor necrosis factor (TNF) receptor recruits TNF for signaling by the 55 kDa TNF receptor. J Biol Chem 1993; 268: 18542–18548
   PubMed Web of Science ®Google Scholar
• Tartaglia LA, Goeddel DV, Reynolds C, Figari IS, Weber RF, Fendly BM, Palladino MA, Jr. Stimulation of human T-cell proliferation by specific activation of the 75 kDa tumor necrosis factor receptor. J Immunol 1993; 151: 4637–4641
   PubMed Web of Science ®Google Scholar
• Hofmann C, Lorenz K, Braithwaite SS, Colca JR, Palazuk BJ, Hotamisligil GS, Spiegelman BM. Altered gene expression for tumor necrosis factor-alpha and its receptors during drug and dietary modulation of insulin resistance. Endocrinology 1994; 134: 264–270
   PubMed Web of Science ®Google Scholar
• Shimizu T, Tomita Y, Son K, Nishinarita S, Sawada S, Horie T. Elevation of serum soluble tumour necrosis factor receptors in patients with polymyositis and dermatomyositis. Clin Rheumatol 2000; 19: 352–359
   PubMed Web of Science ®Google Scholar
• Hassan AB, Nikitina-Zake L, Sanjeevi CB, Lundberg IE, Padyukov L. Association of the proinflammatory haplotype (MICA5.1/TNF2/TNFa2/DRB1*03) with polymyositis and dermatomyositis. Arthritis Rheum 2004; 50: 1013–1015
   PubMedGoogle Scholar
• Pachman LM, Liotta-Davis MR, Hong DK, Kinsella TR, Mendez EP, Kinder JM, Chen EH. TNFalpha-308A allele in juvenile dermatomyositis: Association with increased production of tumor necrosis factor alpha, disease duration, and pathologic calcifications. Arthritis Rheum 2000; 43: 2368–2377
   PubMed Web of Science ®Google Scholar
• Nelson DL, Rubin LA, Kurman CC, Fritz ME, Boutin B. An analysis of the cellular requirements for the production of soluble interleukin-2 receptors in vitro. J Clin Immunol 1986; 6: 114–120
   PubMed Web of Science ®Google Scholar
• Rubin LA, Jay G, Nelson DL. The released interleukin 2 receptor binds interleukin 2 efficiently. J Immunol 1986; 137: 3841–3844
   PubMed Web of Science ®Google Scholar
• Jacques Y, Le Mauff B, Boeffard F, Godard A, Soulillou JP. A soluble interleukin 2 receptor produced by a normal alloreactive human T cell clone binds interleukin 2 with low affinity. J Immunol 1987; 139: 2308–2316
   PubMed Web of Science ®Google Scholar
• Isenberg DA, Rowe D, Shearer M, Novick D, Beverley PC. Localization of interferons and interleukin 2 in polymyositis and muscular dystrophy. Clin Exp Immunol 1986; 63: 450–458
   PubMedGoogle Scholar
• McInnes IB, Gracie JA. Interleukin-15: A new cytokine target for the treatment of inflammatory diseases. Curr Opin Pharmacol 2004; 4: 392–397
   PubMed Web of Science ®Google Scholar
• Azimi N, Jacobson S, Leist T, Waldmann TA. Involvement of IL-15 in the pathogenesis of human T lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis: Implications for therapy with a monoclonal antibody directed to the IL-2/15R beta receptor. J Immunol 1999; 163: 4064–4072
   PubMed Web of Science ®Google Scholar
• McInnes IB, Leung BP, Sturrock RD, Field M, Liew FY. Interleukin-15 mediates T cell-dependent regulation of tumor necrosis factor-alpha production in rheumatoid arthritis. Nat Med 1997; 3: 189–195
   PubMed Web of Science ®Google Scholar
• Sugiura T, Harigai M, Kawaguchi Y, Takagi K, Fukasawa C, Ohsako-Higami S, Ohta S, Tanaka M, Hara M, Kamatani N. Increased IL-15 production of muscle cells in polymyositis and dermatomyositis. Int Immunol 2002; 14: 917–924
   PubMedGoogle Scholar
• Quinn LS, Anderson BG, Drivdahl RH, Alvarez B, Argiles JM. Overexpression of interleukin-15 induces skeletal muscle hypertrophy in vitro: Implications for treatment of muscle wasting disorders. Exp Cell Res 2002; 280: 55–63
   PubMed Web of Science ®Google Scholar
• Angiolillo AL, Kanegane H, Sgadari C, Reaman GH, Tosato G. Interleukin-15 promotes angiogenesis in vivo. Biochem Biophys Res Commun 1997; 233: 231–237
   PubMed Web of Science ®Google Scholar
• Harcourt LJ, Holmes AG, Gregorevic P, Schertzer JD, Stupka N, Plant DR, Lynch GS. Interleukin-15 administration improves diaphragm muscle pathology and function in dystrophic mdx mice. Am J Pathol 2005; 166: 1131–1141
   PubMedGoogle Scholar
• Sugiura T, Kawaguchi Y, Harigai M, Takagi K, Ohta S, Fukasawa C, Hara M, Kamatani N. Increased CD40 expression on muscle cells of polymyositis and dermatomyositis: Role of CD40–CD40 ligand interaction in IL-6, IL-8, IL-15, and monocyte chemoattractant protein-1 production. J Immunol 2000; 164: 6593–6600
   PubMed Web of Science ®Google Scholar
• Suzuki J, Morimoto S, Amano H, Tokano Y, Takasaki Y, Hashimoto H. Serum levels of interleukin 15 in patients with rheumatic diseases. J Rheumatol 2001; 28: 2389–2391
   PubMed Web of Science ®Google Scholar
• Sakai T, Kusugami K, Nishimura H, Ando T, Yamaguchi T, Ohsuga M, Ina K, Enomoto A, Kimura Y, Yoshikai Y. Interleukin 15 activity in the rectal mucosa of inflammatory bowel disease. Gastroenterology 1998; 114: 1237–1243
   PubMed Web of Science ®Google Scholar
• McInnes IB, al-Mughales J, Field M, Leung BP, Huang FP, Dixon R, Sturrock RD, Wilkinson PC, Liew FY. The role of interleukin-15 in T-cell migration and activation in rheumatoid arthritis. Nat Med 1996; 2: 175–182
   PubMed Web of Science ®Google Scholar
• Gonzalez-Alvaro I, Ortiz AM, Garcia-Vicuna R, Balsa A, Pascual-Salcedo D, Laffon A. Increased serum levels of interleukin-15 in rheumatoid arthritis with long- term disease. Clin Exp Rheumatol 2003; 21: 639–642
   PubMed Web of Science ®Google Scholar
• Giri JG, Ahdieh M, Eisenman J, Shanebeck K, Grabstein K, Kumaki S, Namen A, Park LS, Cosman D, Anderson D. Utilization of the beta and gamma chains of the IL-2 receptor by the novel cytokine IL-15. EMBO J 1994; 13: 2822–2830
   PubMed Web of Science ®Google Scholar
• Tagaya Y, Bamford RN, DeFilippis AP, Waldmann TA. IL-15: A pleiotropic cytokine with diverse receptor/signaling pathways whose expression is controlled at multiple levels. Immunity 1996; 4: 329–336
   PubMed Web of Science ®Google Scholar
• Anderson DM, Kumaki S, Ahdieh M, Bertles J, Tometsko M, Loomis A, Giri J, Copeland NG, Gilbert DJ, Jenkins NA, et al. Functional characterization of the human interleukin-15 receptor alpha chain and close linkage of IL15RA and IL2RA genes. J Biol Chem 1995; 270: 29862–29869
   PubMed Web of Science ®Google Scholar
• Riechman SE, Balasekaran G, Roth SM, Ferrell RE. Association of interleukin-15 protein and interleukin-15 receptor genetic variation with resistance exercise training responses. J Appl Physiol 2004; 97: 2214–2219
   PubMed Web of Science ®Google Scholar
• Lotze MT, Tracey KJ. High-mobility group box 1 protein (HMGB1): Nuclear weapon in the immune arsenal. Nat Rev Immunol 2005; 5: 331–342
   PubMed Web of Science ®Google Scholar
• Wang H, Bloom O, Zhang M, Vishnubhakat JM, Ombrellino M, Che J, Frazier A, Yang H, Ivanova S, Borovikova L, et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science 1999; 285: 248–251
   PubMed Web of Science ®Google Scholar
• Wang H, Vishnubhakat JM, Bloom O, Zhang M, Ombrellino M, Sama A, Tracey KJ. Proinflammatory cytokines (tumor necrosis factor and interleukin 1) stimulate release of high mobility group protein-1 by pituicytes. Surgery 1999; 126: 389–392
   PubMed Web of Science ®Google Scholar
• Bustin M. At the crossroads of necrosis and apoptosis: Signaling to multiple cellular targets by HMGB1. Sci STKE 2002; 2002: PE39
   PubMedGoogle Scholar
• Andersson U, Wang H, Palmblad K, Aveberger AC, Bloom O, Erlandsson-Harris H, Janson A, Kokkola R, Zhang M, Yang H, et al. High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. J Exp Med 2000; 192: 565–570
   PubMed Web of Science ®Google Scholar
• Ulfgren AK, Grundtman C, Borg K, Alexanderson H, Andersson U, Harris HE, Lundberg IE. Down-regulation of the aberrant expression of the inflammation mediator high mobility group box chromosomal protein 1 in muscle tissue of patients with polymyositis and dermatomyositis treated with corticosteroids. Arthritis Rheum 2004; 50: 1586–1594
   PubMed Web of Science ®Google Scholar
• Kokkola R, Sundberg E, Ulfgren AK, Palmblad K, Li J, Wang H, Ulloa L, Yang H, Yan XJ, Furie R, et al. High mobility group box chromosomal protein 1: A novel proinflammatory mediator in synovitis. Arthritis Rheum 2002; 46(10)2598–2603
   PubMedGoogle Scholar
• Jung F, Neuer G, Bautz FA. Antibodies against a peptide sequence located in the linker region of the HMG-1/2 box domains in sera from patients with juvenile rheumatoid arthritis. Arthritis Rheum 1997; 40: 1803–1809
   PubMedGoogle Scholar
• Bustin M, Reisch J, Einck L, Klippel JH. Autoantibodies to nucleosomal proteins: Antibodies to HMG-17 in autoimmune diseases. Science 1982; 215: 1245–1247
   PubMedGoogle Scholar
• Ayer LM, Rubin RL, Dixon GH, Fritzler MJ. Antibodies to HMG proteins in patients with drug-induced autoimmunity. Arthritis Rheum 1994; 37: 98–103
   PubMed Web of Science ®Google Scholar
• Ayer LM, Senecal JL, Martin L, Dixon GH, Fritzler MJ. Antibodies to high mobility group proteins in systemic sclerosis. J Rheumatol 1994; 21: 2071–2075
   PubMedGoogle Scholar
• Hori O, Brett J, Slattery T, Cao R, Zhang J, Chen JX, Nagashima M, Lundh ER, Vijay S, Nitecki D, et al. The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. Mediation of neurite outgrowth and co-expression of rage and amphoterin in the developing nervous system. J Biol Chem 1995; 270: 25752–25761
   PubMed Web of Science ®Google Scholar
• Su DM, Wang J, Lin Q, Cooper MD, Watanabe T. Interferons alpha/beta inhibit IL-7-induced proliferation of CD4 − CD8 − CD3 − CD44+ CD25+ thymocytes, but do not inhibit that of CD4 − CD8 − CD3 − CD44 − CD25 − thymocytes. Immunology 1997; 90: 543–549
   PubMedGoogle Scholar
• Uzel G, Pachman LM. Cytokines in juvenile dermatomyositis pathophysiology: Potential and challenge. Curr Opin Rheumatol 2003; 15: 691–697
   PubMedGoogle Scholar
• Greenberg SA, Pinkus JL, Pinkus GS, Burleson T, Sanoudou D, Tawil R, Barohn RJ, Saperstein DS, Briemberg HR, Ericsson M, et al. Interferon-alpha/beta-mediated innate immune mechanisms in dermatomyositis. Ann Neurol 2005; 57: 664–678
   PubMed Web of Science ®Google Scholar
• Novick D, Cohen B, Rubinstein M. Soluble interferon-alpha receptor molecules are present in body fluids. FEBS Lett 1992; 314: 445–448
   PubMed Web of Science ®Google Scholar
• Chomarat P, Rissoan MC, Banchereau J, Miossec P. Interferon gamma inhibits interleukin 10 production by monocytes. J Exp Med 1993; 177: 523–527
   PubMed Web of Science ®Google Scholar
• Varga J, Olsen A, Herhal J, Constantine G, Rosenbloom J, Jimenez SA. Interferon-gamma reverses the stimulation of collagen but not fibronectin gene expression by transforming growth factor-beta in normal human fibroblasts. Eur J Clin Invest 1990; 20: 487–493
   PubMed Web of Science ®Google Scholar
• Raju R, Vasconcelos O, Granger R, Dalakas MC. Expression of IFN-gamma-inducible chemokines in inclusion body myositis. J Neuroimmunol 2003; 141: 125–131
   PubMed Web of Science ®Google Scholar
• Kalovidouris AE. The role of cytokines in polymyositis: Interferon-gamma induces class II and enhances class I major histocompatibility complex antigen expression on cultured human muscle cells. J Lab Clin Med 1992; 120: 244–251
   PubMedGoogle Scholar
• Bao SS, King NJ, dos Remedios CG. Elevated MHC class I and II antigens in cultured human embryonic myoblasts following stimulation with gamma-interferon. Immunol Cell Biol 1990; 68(Pt 4)235–241
   PubMedGoogle Scholar
• Finbloom DS, Wahl LM, Winestock KD. The receptor for interferon-gamma on human peripheral blood monocytes consists of multiple distinct subunits. J Biol Chem 1991; 266: 22545–22548
   PubMedGoogle Scholar
• Choi P, Reiser H. IL-4: Role in disease and regulation of production. Clin Exp Immunol 1998; 113: 317–319
   PubMed Web of Science ®Google Scholar
• Doucet C, Brouty-Boye D, Pottin-Clemenceau C, Canonica GW, Jasmin C, Azzarone B. Interleukin (IL)4 and IL-13 act on human lung fibroblasts. Implication in asthma. J Clin Invest 1998; 101: 2129–2139
   PubMed Web of Science ®Google Scholar
• Kotsimbos TC, Ghaffar O, Minshall EM, Humbert M, Durham SR, Pfister R, Menz G, Kay AB, Hamid QA. Expression of the IL-4 receptor alpha-subunit is increased in bronchial biopsy specimens from atopic and nonatopic asthmatic subjects. J Allergy Clin Immunol 1998; 102: 859–866
   PubMedGoogle Scholar
• Moseley TA, Haudenschild DR, Rose L, Reddi AH. Interleukin-17 family and IL-17 receptors. Cytokine Growth Factor Rev 2003; 14: 155–174
   PubMed Web of Science ®Google Scholar
• Chabaud M, Durand JM, Buchs N, Fossiez F, Page G, Frappart L, Miossec P. Human interleukin-17: A T cell-derived proinflammatory cytokine produced by the rheumatoid synovium. Arthritis Rheum 1999; 42: 963–970
   PubMed Web of Science ®Google Scholar
• Chevrel G, Page G, Granet C, Streichenberger N, Varennes A, Miossec P. Interleukin-17 increases the effects of IL-1 beta on muscle cells: Arguments for the role of T cells in the pathogenesis of myositis. J Neuroimmunol 2003; 137: 125–133
   PubMed Web of Science ®Google Scholar
• Jovanovic DV, Di Battista JA, Martel-Pelletier J, Jolicoeur FC, He Y, Zhang M, Mineau F, Pelletier JP. IL-17 stimulates the production and expression of proinflammatory cytokines, IL-beta and TNF-alpha, by human macrophages. J Immunol 1998; 160: 3513–3521
   PubMed Web of Science ®Google Scholar
• Chabaud M, Fossiez F, Taupin JL, Miossec P. Enhancing effect of IL-17 on IL-1-induced IL-6 and leukemia inhibitory factor production by rheumatoid arthritis synoviocytes and its regulation by Th2 cytokines. J Immunol 1998; 161: 409–414
   PubMed Web of Science ®Google Scholar
• Yao Z, Spriggs MK, Derry JM, Strockbine L, Park LS, VandenBos T, Zappone JD, Painter SL, Armitage RJ. Molecular characterization of the human interleukin (IL)-17 receptor. Cytokine 1997; 9: 794–800
   PubMed Web of Science ®Google Scholar
• Sehgal PB, Wang L, Rayanade R, Pan H, Margulies L. Interleukin-6-type cytokines. Ann N Y Acad Sci 1995; 762: 1–14
   PubMedGoogle Scholar
• Hirano T. The biology of interleukin-6. Chem Immunol 1992; 51: 153–180
   PubMedGoogle Scholar
• May LT, Ghrayeb J, Santhanam U, Tatter SB, Sthoeger Z, Helfgott DC, Chiorazzi N, Grieninger G, Sehgal PB. Synthesis and secretion of multiple forms of beta 2-interferon/B-cell differentiation factor 2/hepatocyte-stimulating factor by human fibroblasts and monocytes. J Biol Chem 1988; 263: 7760–7766
   PubMed Web of Science ®Google Scholar
• Helfgott DC, May LT, Sthoeger Z, Tamm I, Sehgal PB. Bacterial lipopolysaccharide (endotoxin) enhances expression and secretion of beta 2 interferon by human fibroblasts. J Exp Med 1987; 166: 1300–1309
   PubMedGoogle Scholar
• Gibbons R, Martinez O, Matli M, Heinzel F, Bernstein M, Warren R. Recombinant IL-4 inhibits IL-6 synthesis by adherent peripheral blood cells in vitro. Lymphokine Res 1990; 9: 283–293
   PubMedGoogle Scholar
• Kikutani H, Taga T, Akira S, Kishi H, Miki Y, Saiki O, Yamamura Y, Kishimoto T. Effect of B cell differentiation factor (BCDF) on biosynthesis and secretion of immunoglobulin molecules in human B cell lines. J Immunol 1985; 134: 990–995
   PubMed Web of Science ®Google Scholar
• Vercelli D, Jabara HH, Arai K, Yokota T, Geha RS. Endogenous interleukin 6 plays an obligatory role in interleukin 4-dependent human IgE synthesis. Eur J Immunol 1989; 19: 1419–1424
   PubMedGoogle Scholar
• Ostrowski K, Rohde T, Zacho M, Asp S, Pedersen BK. Evidence that interleukin-6 is produced in human skeletal muscle during prolonged running. J Physiol 1998; 508(Pt 3)949–953
   PubMed Web of Science ®Google Scholar
• Penkowa M, Keller C, Keller P, Jauffred S, Pedersen BK. Immunohistochemical detection of interleukin-6 in human skeletal muscle fibers following exercise. FASEB J 2003; 17: 2166–2168
   PubMed Web of Science ®Google Scholar
• Steensberg A, Fischer CP, Keller C, Moller K, Pedersen BK. IL-6 enhances plasma IL-1ra, IL-10, and cortisol in humans. Am J Physiol Endocrinol Metab 2003; 285: E433–E437
   PubMed Web of Science ®Google Scholar
• Steensberg A, Toft AD, Bruunsgaard H, Sandmand M, Halkjaer-Kristensen J, Pedersen BK. Strenuous exercise decreases the percentage of type 1 T cells in the circulation. J Appl Physiol 2001; 91: 1708–1712
   PubMed Web of Science ®Google Scholar
• Honda M, Yamamoto S, Cheng M, Yasukawa K, Suzuki H, Saito T, Osugi Y, Tokunaga T, Kishimoto T. Human soluble IL-6 receptor: Its detection and enhanced release by HIV infection. J Immunol 1992; 148: 2175–2180
   PubMed Web of Science ®Google Scholar
• Muller-Newen G, Kohne C, Keul R, Hemmann U, Muller-Esterl W, Wijdenes J, Brakenhoff JP, Hart MH, Heinrich PC. Purification and characterization of the soluble interleukin-6 receptor from human plasma and identification of an isoform generated through alternative splicing. Eur J Biochem 1996; 236: 837–842
   PubMedGoogle Scholar
• Keul R, Heinrich PC, Muller-newen G, Muller K, Woo P. A possible role for soluble IL-6 receptor in the pathogenesis of systemic onset juvenile chronic arthritis. Cytokine 1998; 10: 729–734
   PubMed Web of Science ®Google Scholar
• Salvi M, Girasole G, Pedrazzoni M, Passeri M, Giuliani N, Minelli R, Braverman LE, Roti E. Increased serum concentrations of interleukin-6 (IL-6) and soluble IL-6 receptor in patients with Graves' disease. J Clin Endocrinol Metab 1996; 81: 2976–2979
   PubMed Web of Science ®Google Scholar
• Hirano T, Nakajima K, Hibi M. Signaling mechanisms through gp130: A model of the cytokine system. Cytokine Growth Factor Rev 1997; 8: 241–252
   PubMedGoogle Scholar
• Chen W, Frank ME, Jin W, Wahl SM. TGF-beta released by apoptotic T cells contributes to an immunosuppressive milieu. Immunity 2001; 14: 715–725
   PubMed Web of Science ®Google Scholar
• Espevik T, Waage A, Faxvaag A, Shalaby MR. Regulation of interleukin-2 and interleukin-6 production from T-cells: Involvement of interleukin-1 beta and transforming growth factor-beta. Cell Immunol 1990; 126: 47–56
   PubMed Web of Science ®Google Scholar
• Muzio M, Sironi M, Polentarutti N, Mantovani A, Colotta F. Induction by transforming growth factor-beta 1 of the interleukin-1 receptor antagonist and of its intracellular form in human polymorphonuclear cells. Eur J Immunol 1994; 24: 3194–3198
   PubMedGoogle Scholar
• Rich S, Seelig M, Lee HM, Lin J. Transforming growth factor beta 1 costimulated growth and regulatory function of staphylococcal enterotoxin B-responsive CD8+T cells. J Immunol 1995; 155: 609–618
   PubMedGoogle Scholar
• Confalonieri P, Bernasconi P, Cornelio F, Mantegazza R. Transforming growth factor-beta 1 in polymyositis and dermatomyositis correlates with fibrosis but not with mononuclear cell infiltrate. J Neuropathol Exp Neurol 1997; 56: 479–484
   PubMedGoogle Scholar
• Shull MM, Ormsby I, Kier AB, Pawlowski S, Diebold RJ, Yin M, Allen R, Sidman C, Proetzel G, Calvin D, et al. Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease. Nature 1992; 359: 693–699
   PubMed Web of Science ®Google Scholar
• Yaswen L, Kulkarni AB, Fredrickson T, Mittleman B, Schiffman R, Payne S, Longenecker G, Mozes E, Karlsson S. Autoimmune manifestations in the transforming growth factor-beta 1 knockout mouse. Blood 1996; 87: 1439–1445
   PubMed Web of Science ®Google Scholar
• Roberts AB, Sporn MB. Physiological actions and clinical applications of transforming growth factor-beta (TGF-beta). Growth Factors 1993; 8: 1–9
   PubMed Web of Science ®Google Scholar
• Efthimiou P, Markenson JA. Role of biological agents in immune-mediated inflammatory diseases. South Med J 2005; 98: 192–204
   PubMedGoogle Scholar
• Hengstman GJ, van den Hoogen FH, Barrera P, Netea MG, Pieterse A, van de Putte LB, van Engelen BG. Successful treatment of dermatomyositis and polymyositis with anti-tumor-necrosis-factor-alpha: Preliminary observations. Eur Neurol 2003; 50: 10–15
   PubMed Web of Science ®Google Scholar
• Hengstman GJ, van den Hoogen FH, van Engelen BG. Treatment of dermatomyositis and polymyositis with anti-tumor necrosis factor-alpha: Long-term follow-up. Eur Neurol 2004; 52: 61–63
   PubMed Web of Science ®Google Scholar
• Dastmalchi M, Grundtman C, Alexandersson H, Einarsdottir H, Nennesmo I, Elvin K, Lundberg IE. Increased signs of inflammation after treatment with infliximab in patients with refractory inflammatory myopathies. Arthritis Rheum 2004; 50(Suppl)S105–S106, Abstract 119, The American College of Rheumatology. San Antonio, Texas, USA, 16.21 October
   Google Scholar
• Sprott H, Glatzel M, Michel BA. Treatment of myositis with etanercept (Enbrel), a recombinant human soluble fusion protein of TNF-alpha type II receptor and IgG1. Rheumatology (Oxford) 2004; 43: 524–526
   PubMed Web of Science ®Google Scholar
• Musial J, Undas A, Celinska-Lowenhoff M. Polymyositis associated with infliximab treatment for rheumatoid arthritis. Rheumatology (Oxford) 2003; 42: 1566–1568
   PubMed Web of Science ®Google Scholar
• Bresnihan B, Alvaro-Gracia JM, Cobby M, Doherty M, Domljan Z, Emery P, Nuki G, Pavelka K, Rau R, Rozman B, et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 1998; 41: 2196–2204
   PubMed Web of Science ®Google Scholar
• Braddock M, Quinn A. Targeting IL-1 in inflammatory disease: New opportunities for therapeutic intervention. Nat Rev Drug Discov 2004; 3: 330–339
   PubMed Web of Science ®Google Scholar
• Becher B, Giacomini PS, Pelletier D, McCrea E, Prat A, Antel JP. Interferon-gamma secretion by peripheral blood T-cell subsets in multiple sclerosis: Correlation with disease phase and interferon-beta therapy. Ann Neurol 1999; 45: 247–250
   PubMed Web of Science ®Google Scholar
• Bongioanni P, Mosti S, Moscato G, Lombardo F, Manildo C, Meucci G. Decreases in T-cell tumor necrosis factor alpha binding with interferon beta treatment in patients with multiple sclerosis. Arch Neurol 1999; 56: 71–78
   PubMedGoogle Scholar
• Kälkner KM, Rönnblom L, Karlsson Parra AK, Bengtsson M, Olsson Y, Öberg K. Antibodies against double-stranded DNA and development of polymyositis during treatment with interferon. QJM 1998; 91: 393–399
   PubMedGoogle Scholar
• Hengstman GJ, Vogels OJ, ter Laak HJ, de Witte T, van Engelen BG. Myositis during long-term interferon-alpha treatment. Neurology 2000; 54: 2186
   PubMedGoogle Scholar
• Dietrich LL, Bridges AJ, Albertini MR. Dermatomyositis after interferon alpha treatment. Med Oncol 2000; 17: 64–69
   PubMed Web of Science ®Google Scholar
• Kokkola R, Li J, Sundberg E, Aveberger AC, Palmblad K, Yang H, Tracey KJ, Andersson U, Harris HE. Successful treatment of collagen-induced arthritis in mice and rats by targeting extracellular high mobility group box chromosomal protein 1 activity. Arthritis Rheum 2003; 48: 2052–2058
   PubMed Web of Science ®Google Scholar